Illumina, Inc. ILMN
We take great care to ensure that the data presented and summarized in this overview for ILLUMINA, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ILMN
View all-
Vanguard Group Inc Valley Forge, PA18.2MShares$2 Billion0.05% of portfolio
-
Black Rock Inc. New York, NY13.8MShares$1.52 Billion0.04% of portfolio
-
State Street Corp Boston, MA6.81MShares$748 Million0.04% of portfolio
-
Edgewood Management LLC Greenwich, CT6.66MShares$731 Million2.46% of portfolio
-
Baillie Gifford & CO5.74MShares$630 Million0.62% of portfolio
-
Loomis Sayles & CO L P4.41MShares$485 Million0.86% of portfolio
-
Geode Capital Management, LLC Boston, MA3.75MShares$412 Million0.05% of portfolio
-
Janus Henderson Group PLC London, X03.68MShares$405 Million0.28% of portfolio
-
Morgan Stanley New York, NY3.61MShares$396 Million0.04% of portfolio
-
Wcm Investment Management, LLC Laguna Beach, CA3.38MShares$371 Million1.31% of portfolio
Latest Institutional Activity in ILMN
Top Purchases
Top Sells
About ILMN
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
Insider Transactions at ILMN
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 16
2024
|
Anna Richo Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,622
+50.0%
|
-
|
May 16
2024
|
Caroline Dorsa Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,622
+17.42%
|
-
|
May 16
2024
|
Scott Gottlieb Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,622
+24.25%
|
-
|
May 16
2024
|
Robert S Epstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,622
+12.53%
|
-
|
May 16
2024
|
Frances Arnold Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,622
+13.23%
|
-
|
May 16
2024
|
Stephen P Macmillan Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,622
+38.84%
|
-
|
May 16
2024
|
Gary S Guthart Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,622
+17.23%
|
-
|
May 16
2024
|
Susan E Siegel Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,622
+19.79%
|
-
|
May 16
2024
|
Philip W Schiller Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,622
+13.85%
|
-
|
May 16
2024
|
Scott B. Ullem Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,622
+37.92%
|
-
|
May 15
2024
|
Caroline Dorsa Director |
SELL
Payment of exercise price or tax liability
|
Direct |
612
-5.87%
|
$70,380
$115.01 P/Share
|
May 15
2024
|
Robert S Epstein Director |
SELL
Payment of exercise price or tax liability
|
Direct |
612
-3.76%
|
$70,380
$115.01 P/Share
|
May 06
2024
|
Christensen Jakob Wedel SVP, Strategy/Corp Development |
BUY
Grant, award, or other acquisition
|
Direct |
3,657
+34.27%
|
-
|
May 06
2024
|
Ankur Dhingra SVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,826
+50.0%
|
-
|
Apr 05
2024
|
Carissa Rollins SVP, Chief Information Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
122
-1.03%
|
$15,494
$127.75 P/Share
|
Mar 28
2024
|
Scott B. Ullem Director |
BUY
Grant, award, or other acquisition
|
Direct |
163
+8.89%
|
$22,331
$137.68 P/Share
|
Mar 05
2024
|
Patricia Leckman SVP, Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,054
+30.88%
|
-
|
Mar 05
2024
|
Charles Dadswell SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Indirect |
6,683
+23.06%
|
-
|
Mar 05
2024
|
Scott D Ericksen VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,971
+21.73%
|
-
|
Mar 05
2024
|
Joydeep Goswami SVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,569
+18.53%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 127K shares |
---|---|
Open market or private purchase | 7.33K shares |
Payment of exercise price or tax liability | 11.1K shares |
---|---|
Open market or private sale | 1.82K shares |